News GSK preps filings for chronic hepatitis B drug bepirovirsen GSK will file its chronic hepatitis B virus therapy bepirovirsen for approval in the first quarter, after it hit the mark in two phase 3 trials.
News Alumis shoots up as its Sotyktu rival aces psoriasis trials Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.
News Genmab ends lung cancer drug development Genmab has decided to stop development of a drug for cancer, acasunlimab for non-small cell lung cancer, following a review of its pipeline.
News Ultragenyx, Mereo's brittle bone drug flames out in trials Two phase 3 trials of Ultragenyx and Mereo's sclerostin inhibitor setrusumab in osteogenesis imperfecta missed their primary efficacy objectives.
News J&J abandons trial of atopic dermatitis drug J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.
News AZ's ATR inhibitor ceralasertib flunks lung cancer test AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.
News FDA follows experts' advice and blocks Capricor DMD therapy The FDA has dashed Capricor's hope of getting approval for its cell therapy for Duchenne muscular dystrophy, wreaking havoc with its share price.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.